Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector

Work, L.M. , Reynolds, P. N. and Baker, A. H. (2004) Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector. Genetic Vaccines and Therapy, 2(1), p. 14. (doi: 10.1186/1479-0556-2-14)

22841.pdf - Published Version
Available under License Creative Commons Attribution.



The establishment of efficient gene delivery to target human tissue is a major obstacle for transition of gene therapy from the pre-clinical phases to the clinic. The poor long-term patency rates for coronary artery bypass grafting (CABG) is a major clinical problem that lacks an effective and proven pharmacological intervention. Late vein graft failure occurs due to neointima formation and accelerated atherosclerosis. Since CABG allows a clinical window of opportunity to genetically modify vein ex vivo prior to grafting it represents an ideal opportunity to develop gene-based therapies. Adenoviral vectors have been frequently used for gene delivery to vein ex vivo and pre-clinical studies have shown effective blockade in neointima development by overexpression of candidate therapeutic genes. However, high titers of adenovirus are required to achieve sufficient gene delivery to provide therapeutic benefit. Improvement in the uptake of adenovirus into the vessel wall would therefore be of benefit. Here we determined the ability of an adenovirus serotype 5 vector genetically-engineered with the RGD-4C integrin targeting peptide inserted into the HI loop (Ad-RGD) to improve the transduction of human saphenous vein smooth muscle cells (HSVSMC), endothelial cells (HSVEC) and intact saphenous vein compared to a non-modified virus (Ad-CTL). We exposed each cell type to virus for 10, 30 or 60 mins and measured transgene at 24 h post infection. For both HSVSMC and HSVEC Ad-RGD mediated increased transduction, with the largest increases observed in HSVSMC. When the experiments were repeated with intact human saphenous vein (the ultimate clinical target for gene therapy), again Ad-RGD mediated higher levels of transduction, at all clinically relevant exposures times (10, 30 and 60 mins tissue:virus exposure). Our study demonstrates the ability of peptide-modified Ad vectors to improve transduction to human vein graft cells and tissue and has important implications for gene therapy for CABG.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Baker, Professor Andrew and Work, Dr Lorraine
Authors: Work, L.M., Reynolds, P. N., and Baker, A. H.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Genetic Vaccines and Therapy
Publisher:BioMed Central
ISSN (Online):1479-0556
Copyright Holders:Copyright © 2004 The Authors
First Published:First published in Genetic Vaccines and Therapy 2(1):14
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record